B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Blood

• Publication date

  2006-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2005-09-3552PMID 16304043PMCID PMC1895377
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Waldenström macroglobulinaemia

  2007cited by this paper
• Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders.

  2006cited by this paper
• Monoclonal gammopathies of undetermined significance.

  2005cited by this paper
• Waldenström's macroglobulinemia.

  2005cited by this paper
• Cryoglobulin‐induced cytokine production via FcγRIIa: inverse effects of complement blockade on the production of TNF‐α and IL‐10. Implications for the growth of malignant B‐cell clones

  2005cited by this paper
• The role of APRIL and BAFF in lymphocyte activation.

  2005cited by this paper
• Discovery of high‐affinity peptide binders to BLyS by phage display

  2005cited by this paper
• Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors.

  2005cited by this paper
• The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.

  2005cited by this paper
• Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome.

  2004cited by this paper
• B Cell-Activating Factor Belonging to the TNF Family Acts through Separate Receptors to Support B Cell Survival and T Cell-Independent Antibody Formation

  2004cited by this paper
• BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells

  2004cited by this paper
• Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.

  2004cited by this paper
• TNF Family Member B Cell-Activating Factor (BAFF) Receptor-Dependent and -Independent Roles for BAFF in B Cell Physiology1

  2004cited by this paper
• BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.

  2004cited by this paper
• Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway.

  2004cited by this paper
• Studies of Structure-Activity Relations of Complement Inhibitor Compstatin1

  2003cited by this paper
• G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS

  2003cited by this paper
• The TNF family members BAFF and APRIL: the growing complexity.

  2003cited by this paper
• The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome

  2003cited by this paper
• BAFF AND APRIL: a tutorial on B cell survival.

  2003cited by this paper
• BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

  2003cited by this paper
• B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

  2003cited by this paper
• Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

  2003cited by this paper
• Waldenström macroglobulinaemia.

  2003cited by this paper
• Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival.

  2002cited by this paper
• Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts.

  2002cited by this paper
• Monoclonal gammopathies of undetermined significance.

  2002cited by this paper
• BAFF: A fundamental survival factor for B cells

  2002cited by this paper
• Cutting Edge: BLyS Enables Survival of Transitional and Mature B Cells Through Distinct Mediators1

  2002cited by this paper
• BLyS and BLyS receptor expression in non-Hodgkin's lymphoma.

  2002cited by this paper
• DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL

  2002cited by this paper
• Serum levels of IL‐6 and its soluble receptor (sIL‐6R) in Waldenström's macroglobulinemia

  2001cited by this paper
• BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF

  2001cited by this paper
• The TNF and TNF Receptor Review Superfamilies: Integrating Mammalian Biology

  2001cited by this paper
• Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus1

  2001cited by this paper
• Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

  2001cited by this paper
• Synthesis and release of B-lymphocyte stimulator from myeloid cells.

  2001cited by this paper
• TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

  2000cited by this paper
• Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI Is a High Affinity Receptor for TNF Family Members APRIL and BLyS*

  2000cited by this paper
• Baff Binds to the Tumor Necrosis Factor Receptor–Like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population

  2000cited by this paper
• A Soluble Form of B Cell Maturation Antigen, a Receptor for the Tumor Necrosis Factor Family Member April, Inhibits Tumor Cell Growth

  2000cited by this paper
• Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI.

  2000cited by this paper
• BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth

  1999cited by this paper
• BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.

  1999cited by this paper
• CD3+ T lymphocytes and interleukin 2 in myelomatous blood hyperviscosity syndrome treated with plasmapheresis.

  1998cited by this paper
• Critical role of IL-12 in dendritic cell-induced differentiation of naive B lymphocytes.

  1998cited by this paper
• Bcmd decreases the life span of B-2 but not B-1 cells in A/WySnJ mice.

  1998cited by this paper
• The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily.

  1998cited by this paper
• NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily.

  1997cited by this paper
• Direct binding of IL-12 to human and murine B lymphocytes.

  1996cited by this paper
• Bcmd governs recruitment of new B cells into the stable peripheral B cell pool in the A/WySnJ mouse.

  1996cited by this paper
• Enhancement of Humoral Immunity by Interleukin‐12

  1996cited by this paper
• Waldenstrom's macroglobulinemia.

  1994cited by this paper
• The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed.

  1994cited by this paper
• Propagation of Waldenström's macroglobulinemia cells in vitro and in severe combined immune deficient mice: utility as a preclinical drug screening model.

  1993cited by this paper
• Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice

  1991cited by this paper

• Soluble BCMA as a biomarker reflecting tumor volume and treatment response in Waldenström macroglobulinemia

  2025cites this paper
• Serum B‐Cell Maturation Antigen as a Biomarker for Predicting Outcomes and Monitoring Patients With Waldenström Macroglobulinemia

  2025cites this paper
• Evaluation of B cell maturation antigen (CD269) in comparison to CD138 for identifying multiple myeloma in Egyptian patients

  2025cites this paper
• Soluble BCMA: a window into tumor burden monitoring in Waldenström macroglobulinemia?

  2025cites this paper
• GLI3 Is Required for M2 Macrophage Polarization and M2-Mediated Waldenström Macroglobulinemia Growth and Survival

  2024cites this paper
• Past and present discovery of the BAFF/APRIL system - A bibliometric study from 1999 to 2023.

  2024cites this paper
• The effect of hypoxia on GLI expression and their downstream effect in Waldenström Macroglobulinemia

  2023cites this paper
• B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages

  2022cites this paper
• Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies

  2022cites this paper
• The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma

  2021cites this paper
• Increased Production of B-Cell Activating Cytokines and Altered Peripheral B-Cell Subset Distribution during HIV-Related Classical Hodgkin Lymphoma

  2021cites this paper
• Post‐relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation

  2021cites this paper
• Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

  2021cites this paper
• B-cell maturation antigen expression across hematologic cancers: a systematic literature review

  2020cites this paper
• Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia

  2019cites this paper
• What is new in the treatment of Waldenstrom macroglobulinemia?

  2019cites this paper
• THE ROLE OF THE TUMOR MICROENVIRONMENT IN WALDENSTRÖM MACROGLOBULINEMIA

  2019cites this paper
• Circulatory levels of B‐cell activating factor of the TNF family in patients with diabetic foot ulcer: Association with disease progression

  2019cites this paper
• Targeting IL-6 reduces IgM levels and tumor growth in Waldenström macroglobulinemia

  2019cites this paper
• The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma

  2018cites this paper
• Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

  2018cites this paper
• The Bone Marrow Microenvironment in Waldenström Macroglobulinemia.

  2018cites this paper
• Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.

  2018cites this paper
• The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström’s Macroglobulinemia

  2017cites this paper
• Novel Molecular Mechanism of Regulation of CD40 Ligand by the Transcription Factor GLI2

  2017cites this paper
• B-cell activating factor deficiency suppresses splenomegaly during Leishmania donovani infection.

  2017cites this paper
• Chimeric Antigen Receptor (CAR) therapy for multiple myeloma

  2016cites this paper
• Bone marrow microenvironment in Waldenstrom's Macroglobulinemia.

  2016cites this paper
• Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia.

  2016cites this paper
• Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma

  2016cites this paper
• Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88L265P plasmablasts in vivo.

  2016cites this paper
• Immunoglobulins in the Pathophysiology of Visceral Leishmaniasis

  2016cites this paper
• Modulation of the IL-6 Receptor α Underlies GLI2-Mediated Regulation of Ig Secretion in Waldenström Macroglobulinemia Cells

  2015cites this paper
• Factors Regulating Immunoglobulin Production by Normal and Disease-Associated Plasma Cells

  2015cites this paper
• Waldenström Macroglobulinemia Cells GLI 2-Mediated Regulation of Ig Secretion in Underlies α Modulation of the IL-6 Receptor

  2015cites this paper
• Elevation of serum B-cell activating factor levels during visceral leishmaniasis.

  2014cites this paper
• Maladie de Waldenström ou macroglobulinémie

  2014cites this paper
• Waldenströmovy makroglobulinemie Cytokine Profiles of Multiple Myeloma and Waldenström

  2014cites this paper
• The bone marrow microenvironment in Waldenström macroglobulinemia.

  2013cites this paper
• Targeting the BAFF/APRIL Cytokine Network in Multiple Myeloma

  2013cites this paper
• La maladie de Waldenström ou macroglobulinémie

  2013cites this paper
• A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.

  2013cites this paper
• B Cell Activating Factor Inhibition Impairs Bacterial Immunity by Reducing T Cell-Independent IgM Secretion

  2013cites this paper
• BAFF INHIBITION IMPAIRS BACTERIAL IMMUNITY BY 1 REDUCING T CELL-INDEPENDENT IgM SECRETION 2 3

  2013cites this paper
• APRIL generate survival and proliferation signals in response to BAFF and Hodgkin lymphoma cells express TACI and BCMA receptors and

  2013cites this paper
• Regulatory roles of the tumor necrosis factor receptor BCMA.

  2012cites this paper
• Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma.

  2012cites this paper
• Cytokines as regulators of proliferation and survival of healthy and malignant peripheral B cells.

  2012cites this paper
• The determination of BAFF protein in patients with monoclonal gammopathies - first experience

  2012cites this paper
• Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival

  2012cites this paper
• New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia

  2011cites this paper
• Phase I study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenström's macroglobulinemia.

  2011cites this paper
• Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1.

  2011cites this paper
• IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.

  2011cites this paper
• Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.

  2011cites this paper
• Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center.

  2011cites this paper
• The bone marrow niche in Waldenström's macroglobulinemia.

  2011cites this paper
• B‐cell stage and context‐dependent requirements for survival signals from BAFF and the B‐cell receptor

  2010cites this paper
• Cytokines in the microenvironment of Waldenström's macroglobulinemia.

  2009cites this paper
• Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.

  2009cites this paper
• Targeting of BAFF and APRIL for autoimmunity and oncology.

  2009cites this paper
• APRIL is overexpressed in cancer: link with tumor progression

  2009cites this paper
• Expression and localization of rabbit B-cell activating factor (BAFF) and its specific receptor BR3 in cells and tissues of the rabbit immune system.

  2009cites this paper
• Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study

  2009cites this paper
• Expression, characterization of recombinant human soluble BAFF secreted from CHO cell

  2009cites this paper
• Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis

  2009cites this paper
• Systemic Immune-Based Rheumatic Diseases: Blissless States of BLySfulness

  2009cites this paper
• Tipping the Scales of Survival: The Role of BLyS in B-Cell Malignancies

  2009influential citation
• The Role of BAFF and APRIL in Regulating Human B-Cell Behaviour: Implications for Disease Pathogenesis

  2009cites this paper
• Factor activador de célula B perteneciente a la familia del TNF (BAFF): Blanco terapéutico por su papel en autoinmunidad

  2008cites this paper
• CDDO-imidazolide mediated inhibition of malignant cell growth in Waldenström macroglobulinemia.

  2008cites this paper
• Response: Decoy receptor 3 (DcR3), a pleiotropic immunomodulator

  2008cites this paper
• Waldenström's Macroglobulinemia: new therapeutic options

  2008cites this paper
• Anomalies chromosomiques et macroglobulinémie de Waldenström

  2008cites this paper
• WSU-WM and BCWM.1 should not be assumed to represent Waldenström macroglobulinemia cell lines.

  2008cites this paper
• The HMG‐CoA inhibitor, simvastatin, triggers in vitro anti‐tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia

  2008influential citation
• Indolent lymphomas other than follicular and marginal zone lymphomas.

  2008cites this paper
• Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells.

  2008cites this paper
• Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.

  2008cites this paper
• Protein kinase C–associated kinase is required for NF- (cid:1) B signaling and survival in diffuse large B-cell lymphoma cells

  2008cites this paper
• Waldenstrom macroglobulinemia.

  2008cites this paper
• TRAIL receptors in the serum of patients with B-cell chronic lymphocytic leukemia.

  2008cites this paper
• [Chromosomal abnormalities and Waldenström macroglobulinemia].

  2008cites this paper
• Overexpression of B cell-activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma.

  2008cites this paper
• Protein kinase C–associated kinase is required for NF-κB signaling and survival in diffuse large B-cell lymphoma cells

  2008cites this paper
• Targeting B-lymphocyte stimulator (BLyS) in immune-based rheumatic diseases: a therapeutic promise waiting to be fulfilled

  2007cites this paper
• Novel Options of Therapy in Waldenstro¨m Macroglobulinemia

  2007cites this paper
• Novel agents in the treatment of Waldenström's macroglobulinemia.

  2007cites this paper
• Waldenström macroglobulinaemia

  2007cites this paper
• High serum levels of B‐lymphocyte stimulator are associated with clinical–pathological features and outcome in classical Hodgkin lymphoma

  2007cites this paper
• Review in translational hematology Waldenström macroglobulinemia

  2007cites this paper
• Waldenström macroglobulinemia.

  2007cites this paper
• B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling.

  2007cites this paper
• Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.

  2007cites this paper
• Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL.

  2007cites this paper
• ROLE DES MEMBRES DE LA FAMILLE BAFF/APRIL DANS LE MYELOME MULTIPLE : IMPLICATIONS PHYSIOPATHOLOGIQUES ET INTERET THERAPEUTIQUE

  2006cites this paper
• Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

  2006cites this paper
• New drugs for the treatment of advanced-stage diffuse large cell lymphomas.

  2006cites this paper
• BAFF, APRIL and human B cell disorders.

  2006cites this paper
• Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia.

  2006cites this paper